Wednesday, 20 January 2021

China NMPA approves CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy for thalassemia

China NMPA approves CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy for thalassemia admin Wed, 01/20/2021 - 16:05

source https://www.pharmatutor.org/pharma-news/2021/china-nmpa-approves-crispr-cas-9-gene-editing-hematopoietic-stem-cell-therapy-for-thalassemia
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Career for Pharmacy and Biotech at National Agri-Food and Biomanufacturing Institute

Positions: Junior Research Fellow (JRF) (One) Master’s Degree from a recognized University/Institute in M.Sc. Chemistry - Organic / Physical...